

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

INFORMATION DISCLOSURE STATEMENT
FOR PATENT

APPLICANT:

Jiang X. Behan *et al.*

(Use several sheets if necessary)

FILING DATE:

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>[initials]</i>	5,817,480	10/06/98	Murry <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>[initials]</i>	WO 00/31258	06/02/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>[initials]</i>	Voet <i>et al.</i> , <i>Biochemistry</i> , John Wiley & Sons, Inc., pp. 126-128 and 228-234 (1990).
<i>[initials]</i>	Birren <i>et al.</i> , "Homo sapiens chromosome 18, clone RP11-178F10 unpublished", EMBL SEQUENCE Database, abstract.
<i>[initials]</i>	Oda <i>et al.</i> , "Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes", <i>J. Biological Chem.</i> , vol. 275, no. 47, pp. 36781-36786 (2000).
<i>[initials]</i>	Lovenberg <i>et al.</i> , "Cloning and Functional Expression of the Human Histamine H3 Receptor", <i>Molecular Pharmacology</i> , vol. 55, pp. 1101-1107 (1999).
<i>[initials]</i>	Raible <i>et al.</i> , "Pharmacologic Characterization of a Novel Histamine Receptor on Human Eosinophils", <i>Am. J. Respiratory Critical Care Med.</i> , vol. 149, pp. 1506-1511 (1994).
<i>[initials]</i>	West <i>et al.</i> , "Identification of Two H3-Histamine Receptor Subtypes", <i>Molecular Pharmacology</i> , vol. 38, pp. 610-613 (1990).
<i>[initials]</i>	Mikayama, "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor", <i>Proc. Natl. Acad. Sci.</i> , vol. 90, pp. 10056-10060 (1993).
<i>[initials]</i>	Birre, "Homo sapiens chromosome 18 clone hRPK.178_F_map 18", Accession Number AC007922 (June 26, 1999).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTC/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/616,088
Filing Date	07/08/2003
First Named Inventor	BEHAN, Jiang X.
Art Unit	1649
Examiner Name	John D Ulm
Attorney Docket Number	CN010698Q US

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

Examiner Signature		Date Considered	4/24/06
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 508. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PAGE 4/6 * RCVD AT 2/14/2006 1:03:55 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/31 * DNIS:2738300 * CSID:908 298 5405 * DURATION (mm-ss):01-58